We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-30.91%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$5.08M
AUM Growth
-$11.6M
Cap. Flow
-$8.83M
Cap. Flow %
-173.72%
Top 10 Hldgs %
99.52%
Holding
15
New
–
Increased
1
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$34.1K

Top Sells

Rank Stock Value
1
XERS icon
Xeris Biopharma Holdings
XERS
+$6.83M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$1.65M
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$324K
4
CBIO
Crescent Biopharma
CBIO
+$50.9K

Sector Composition

Rank Sector Weight
1 Healthcare 87.74%
2 Financials 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
1
Rezolute
RZLT
$480M
$3.83M 75.28%
1,318,967
– –
GLD icon
2
SPDR Gold Trust
GLD
$131B
$374K 7.36%
1,298
+129
+11% +$34.1K
BRK.B icon
3
Berkshire Hathaway Class B
BRK.B
$1.07T
$249K 4.9%
467
-666
-59% -$324K
DFTX
4
Definium Therapeutics
DFTX
$5.73B
$199K 3.92%
34,073
– –
BCAX
5
Bicara Therapeutics
BCAX
$1.78B
$143K 2.81%
10,941
– –
CMPX icon
6
Compass Therapeutics
CMPX
$373M
$82.6K 1.63%
43,465
– –
LXEO icon
7
Lexeo Therapeutics
LXEO
$366M
$61.9K 1.22%
17,851
– –
KYTX icon
8
Kyverna Therapeutics
KYTX
$450M
$44.4K 0.87%
22,981
– –
CRDF icon
9
Cardiff Oncology
CRDF
$64.3M
$41.7K 0.82%
13,287
– –
IKT icon
10
Inhibikase Therapeutics
IKT
$366M
$35.9K 0.71%
16,393
– –
ACET icon
11
Adicet Bio
ACET
$72.8M
$13.2K 0.26%
1,093
– –
CNTX icon
12
Context Therapeutics
CNTX
$56.4M
$11.3K 0.22%
18,403
– –
CBIO
13
Crescent Biopharma
CBIO
$602M
– –
-2,036
Closed -$50.9K
SPY icon
14
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-2,823
Closed -$1.65M
XERS icon
15
Xeris Biopharma Holdings
XERS
$1.44B
– –
-2,015,157
Closed -$6.83M

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2025 Portfolio in Review

As of Q1 2025, Caxton Corporation held 15 positions worth $5.08M, down 69% from $16.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation withdrew a net $8.83M in Q1 2025, closing 3 positions and reducing 1 holding. Its most notable exit was Xeris Biopharma Holdings, an estimated $6.83M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Caxton Corporation added an estimated $34.1K to SPDR Gold Trust.

  • Caxton Corporation added most to SPDR Gold Trust in Q1 2025, an estimated $34.1K increase.
  • Caxton Corporation's biggest Q1 2025 reduction was Berkshire Hathaway Class B, cutting an estimated $324K.
  • Caxton Corporation fully exited Xeris Biopharma Holdings in Q1 2025, selling an estimated $6.83M.
  • Caxton Corporation's ten largest holdings make up 100% of its $5.08M portfolio in Q1 2025.
  • Caxton Corporation opened 0 new positions and closed 3 in Q1 2025.
  • Caxton Corporation's portfolio value fell 69% quarter-over-quarter to $5.08M.

Based on Caxton Corporation's 13F filing for Q1 2025, filed 15 May 2025.